All you need to know about Silex Systems Placement

Highlights:

• Silex Systems Limited completed an AU$120 million institutional placement.
• The funds raised will be used to speed up the commercialisation of SILEX laser enrichment technology.
• Qualified shareholders are presented with the chance to purchase New Shares worth a maximum of AU$30,000 through the SPP.

Silex Systems Limited (ASX: SLX) has recently concluded a successful institutional placement (Placement) of AU$120 million at an offer price of AU$4.05 per new share. This news is welcome as it received substantial support from local as well as international investors, including new institutions and existing eligible shareholders. The Placement has generated a considerable amount of funds, which will be combined with the existing cash reserves to expedite the commercialisation process of the innovative SILEX laser enrichment technology.

The primary objective of this acceleration is to capitalise on various strategic market opportunities in:

• Uranium production
• Enrichment, medical isotopes
• Zero -Spin Silicon (ZS-Si)
• Medical isotopes

The New Shares issued under the Placement will have the same ranking as the existing Silex ordinary shares. The New Shares are expected to be allotted on Tuesday, 7 March 2023, and their trading will commence on the same day on the ASX. Silex announced that it would be offering eligible shareholders an opportunity to acquire new shares worth up to AU$30,000 through a non-underwritten Share Purchase Plan (SPP). The aim of this plan is to raise an additional AU$20 million.

The SPP Booklet and Application Form

• The SPP Booklet and Application Form will be made available on the ASX and sent out to eligible shareholders on or around Monday, 13 March 2023.
• The SPP is scheduled to commence on the same day.
• Shareholders who wish to participate in the SPP must submit their Application Forms and payments by 5:00 pm (AEDT) on Thursday, 30 March 2023.
• It is expected that the allotment of the new shares issued under the SPP will take place on Thursday, 6 April 2023.
• This move is aimed at enhancing the financial capacity of the Company and ensuring that it continues to deliver value to its shareholders.

Silex has released an Investor Presentation called "Accelerating SILEX Technology Commercialisation - Equity Raising Presentation," which provides additional information on this matter. On 23 February 2023, Silex requested a halt to its trading activities. In response, Euroz Hartleys Limited and Shaw and Partners Limited were appointed as Joint Bookrunners and Joint Lead Managers for the Placement, while Canaccord Genuity (Australia) Limited acted as Joint Lead Manager.

All in all, Silex Systems Limited has completed an AU$120 million institutional placement, and the funds raised will be used to speed up the commercialisation of SILEX laser enrichment technology. In addition, qualified shareholders are presented with the chance to purchase New Shares worth a maximum of AU$30,000 through the SPP, which could potentially generate an additional AU$20 million in funds. As a result, eligible shareholders have the option to increase their investment and potentially increase their returns.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com